Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
60-80-0
Molecular formula
C11H12N2O
Molecular weight
188.23 g/mol
Drug class
Pyrazolone analgesic and antipyretictopical anti-inflammatory component
Mechanism of action
A pyrazolone derivative with analgesic and antipyretic activity. The precise molecular mechanism is not fully established; inhibition of prostaglandin-mediated pain and fever pathways is considered relevant. Topical ear preparations also provide local analgesic and anti-inflammatory effects.
Indications / reported uses
Systemic relief of pain and fever with authorised formulations.
Local symptomatic relief of ear pain in selected otic preparations, including products used in otitis media.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Phenazone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenazone Permitted Daily Exposure (PDE) report (the Phenazone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenazone Occupational Exposure Limit (OEL) report (the Phenazone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.